ProQR CEO Daniel de Boer invests $261K in open-market purchase
PRQR sits 35% above its 52-week low of $1.33.
Summary
ProQR CEO Daniel de Boer purchased 150,000 shares for $261,000 at $1.74 per share, doubling his direct stake to 300,000 shares.
Key Events · Ownership and Investor Activity · PRQR
-
CEO Open-Market Purchase
CEO Daniel de Boer bought 150,000 shares at $1.74 for $261,000 on July 9, 2026, doubling his direct holdings to 300,000 shares.
-
Financial Impact
The $261,000 purchase represents a significant personal investment by the CEO, signaling confidence in the company's outlook following recent positive clinical data and a successful capital raise.
-
Recent Context
The purchase follows a $59.2 million offering priced at a premium and positive Phase 1 data for AX-0810, and comes after an activist shareholder threatened legal action in June.
Analysis · PRQR · Life Sciences
CEO Daniel de Boer bought 150,000 shares at $1.74, investing $261,000 of his own capital. This is a real-money purchase, not an option exercise, and comes just weeks after the company raised $59.2 million in a premium-priced offering and reported positive Phase 1 data for AX-0810. The buy signals conviction from the top executive at a time when the stock is rebuilding after a recent activist threat and a capital raise.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRQR was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.1M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.